HHorinouchi· @HHorinouchi · X·· 2 天前评分60
正文 · 机器翻译
🆙#ESMO26 快速口头报告 I：#LCSM 转移性 🔥Telisotuzumab Adizutecan 治疗非鳞状非小细胞肺癌（NSQ NSCLC）患者的总生存期（OS）分析：I期首次人体研究 🎙️Dr. David Sommerhalder 🔢2658RO 🎯经 heavily pretreated 患者的中位 OS 为13.8个月（EGFR WT，n=48）和16.2个月（EGFR MUT，n=41） 🎯c-Met 高表达者的 OS 更长（25.2个月，EGFR WT ≥3+/≥10%） ☑️NCT05029882 🔗 https://t.co/E2MIRGnkpb @OncoAlert @Larvol @myESMO @IASLC
热度 0 · 0 赞 · 0 回复 · 0 转发
会议摘要
NCT05029882NCT05029882按 - **标题 / Title：** Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab 对上
- **标题 / Title：** Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab读摘要原文 →来源：HHorinouchi · x.com